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Abstract 
Intestinal acute GVHD (I-aGVHD) is a life-threatening complication after allografting. Non-
invasive bed-side procedures to evaluate extension and treatment response are still lacking. We 
hypothesized that, during I-aGVHD, contrast-enhanced ultrasound sonography (CEUS) could detect 
microcirculation changes (MVC) of the bowel wall (BW) and help to monitor treatment response. 
We prospectively employed CEUS in 83 consecutive patients. Of these, 14 patients with biopsy-
proven intestinal GVHD (I-GVHD) were defined as the study group, whereas 16 patients with 
biopsy-proven stomach GVHD (U-GVHD) without intestinal symptoms, 6 normal volunteers and 4 
patients with neutropenic enterocolitis were defined as the control group. All patients were 
evaluated with both standard ultrasonography (US) and CEUS at the onset of intestinal symptoms, 
during clinical follow-up and at flare of symptoms. Standard US revealed BW thickening of 
multiple intestinal segments, useful to determine the extension of GVHD. CEUS showed MVC, 
which correlated with GVHD activity, treatment response, and predicted flare of intestinal 
symptoms. US and CEUS findings were superimposable at diagnosis and in remission. CEUS was, 
however, more sensitive and specific to identify subclinical activity in patients with clinical relevant 
improvement. These findings were not observed in the control groups. CEUS is a non-invasive, 
easily reproducible bed-side tool useful to monitor I-aGVHD. 
 
 
Introduction 
Intestinal acute GVHD (midgut syndrome, I-aGVHD) is a major cause of non-relapse mortality 
following an allograft.
1, 2
 Diagnosis remains problematic for some patients with this pathology in 
the midgut. Diarrhea volume is generally used to determine the severity of the intestinal 
involvement, but its clinical reliability is highly limited.
3, 4
 Overall, non-invasive specific and 
sensitive techniques to diagnose intestinal GVHD (I-GVHD), to evaluate treatment response and to 
guide the duration of immunosuppression are still lacking. Standard transabdominal 
ultrasonography (US) has already been used for its diagnosis and clinical follow-up,
5, 6, 7
 and, more 
widely, in a variety of other intestinal diseases,
8, 9, 10
 including inflammatory bowel diseases.
11, 12, 13, 
14
 Recent studies have highlighted neovascularization in the early stages of GVHD.
15
 
We previously reported our experience on the use of contrast-enhanced ultrasound (CEUS) during 
I-aGVHD that showed contrast enhancement uptake in the bowel wall (BW).
16
 Schreyer et al.
17, 18
 
have also reported similar findings. 
Standard US is routinely employed to evaluate both small and large intestines in a number of 
intestinal diseases. It is widely employed for both diagnosis and follow-up of inflammatory bowel 
diseases such as Crohn’s disease, where intramural and extramural involvements can accurately be 
evaluated.
19
 Although more rarely, it has also been used for assessing I-GVHD.
20
 
In this study, we have evaluated the changes of the BW during GVHD using both standard US and 
CEUS, which is an easily reproducible ultrasound technique. Real-time microvascular imaging has 
recently been made possible by novel echo-contrast enhancing agents and low mechanical-index 
harmonic sonography. Moreover, CEUS has already been extensively used in active Crohn’s 
disease in which the neovascularization of the small BWs has been described.
21, 22, 23, 24
 Importantly, 
recent studies have highlighted neovascularization in the early stages of GVHD.
15
 
Here, we report the preliminary findings of our prospective study on the role of CEUS as a non-
invasive qualitative and quantitative tool to evaluate extension and monitor I-GVHD. Overall, our 
aims were to evaluate if standard US could detect the extension of I-GVHD; if BW microcirculation 
changes (MVC) by CEUS correlated with clinical symptoms and treatment response; and, finally, if 
CEUS enhancement findings were similar to those seen in active Crohn’s disease.25 
 
Patients and methods 
Patients 
Between 2008 and 2012, we prospectively evaluated 83 consecutive patients admitted for an 
allogeneic transplantation, at the Division of Haematology, University of Pisa, Italy. All patients 
underwent a standard US of the abdominal organs, small and large intestines as part of the pre-
transplant work-up. All patients who developed post-transplant diarrhea and/or vomiting and/or 
abdominal cramping underwent transabdominal US of the small and large intestine as described 
below. The study group consisted of 14/83 patients who developed biopsy-proven I-GVHD. The 
control group consisted of 16 patients who developed biopsy-proven U-GVHD without intestinal 
symptoms;
26
 4 patients who developed neutropenic enterocolitis (NEC) after allografting;
27, 28
 6 
healthy volunteers without any documented diseases. Patient characteristics are summarized in 
Table 1. Median age was 50 years old (range 22–66 years). 
Table 1 - Diagnosis in the study and control group, description of conditioning regimen, 
GVHD prophylaxis, stem cell source, donor, and number and type of events occurred. 
 
 
After ruling out bacterial, fungal and viral infections by routine stool cultures and PCR analyses (for 
herpes viruses, adenovirus, EBV, rotavirus and norovirus), patients with persistent nausea, vomiting 
and diarrhea underwent endoscopy for histological assessment as previously described by Sale et 
al.
3
 and modified by Epstein et al.
29
 CMV infection was ruled out by immunostaining techniques. 
Clinical assessment and grading of GVHD was performed according to standard criteria.
30, 31
 All 
patients and volunteers provided written informed consent and the study was approved by the 
Institutional Review Board according to the Declaration of Helsinki. 
 
Standard sonography methodology 
 
Standard (B-mode) US was performed at bed-side with a portable sonographer (Esaote model My 
Lab 25, Esaote Italia, Florence, Italy) without any preparation, within 24 h from the onset of clinical 
GVHD symptoms. The entire gastrointestinal tract was submitted to a gray-scale ultrasound 
examination (B-mode US). The colon was examined from the cecum to the sigmoid colon. The 
entire small bowel was examined with particular attention to the last portion of the terminal ileum, 
which is the site most commonly involved in GVHD.
5, 6, 7
 The following parameters were assessed: 
(1) bowel wall thickness (BWT) defined as abnormal if 3 mm in the large bowel and 2 mm in 
the duodenum and small bowel;
32
 (2) BW layers: the superficial mucosal interface, the deep 
mucosa, the submucosa, the muscularis propria and the serosa;
33, 34
 (3) degree of dilation;
32, 35
 (4) 
motility;
32
 (5) bowel content defined as gas, food stuff of feces, mixtures of the two, or fluid-
filled;
36
 (6) presence of haustration or dehaustration;
32, 37
 and (7) presence/absence of free 
abdominal fluid in all four quadrants and/or upper abdominal organ pathologies other than GVHD. 
 
CEUS methodology 
 
After standard US, the ultrasound contrast agent was administered i.v. and CEUS was performed on 
diseased intestine
38
 with the same sonographer equipped with contrast-specific real-time imaging 
technology defined as contrast tuned imaging. A second-generation echo-contrast agent, SonoVue 
(Bracco, Milan, Italy), was injected as i.v. bolus into an antecubital vein. Briefly, SonoVue is a non-
nephrotoxic contrast agent that consists of 2.5-μm-diameter microbubbles stabilized with 
phospholipids and filled with sulfur hexafluoride that flow through the pulmonary microcirculation 
and remain within the vascular space.
39
 SonoVue is approved in Europe for clinical use and has a 
wide range of clinical applications.
38, 40, 41
 
Contrast tuned imaging exploits the resonance property of the microbubbles and prevents them 
from bursting during insonation. This allows for real-time imaging of the microcirculation, without 
gray-scale echoes, and provides continuous perfusion data on viscera.
25, 42
 
After injection the contrast agent reaches the intestinal wall in about 10–15 s and its peak 
concentration after approximately 30 s. In the intestine this ‘arterial phase’ is followed by the 
‘venous phase’ in which the contrast agent, after distributing to the whole intestinal capillary bed, is 
exhaled through the lungs.
38
 Continuous imaging was recorded from injection throughout the entire 
arterial and venous phases as previously described by Serra et al.
25
 Distinct digital cine-clips for 
basic US and for CEUS scans were stored for computed analysis. Echo-signal intensity of the 
vascularity of the bowel segments selected with CEUS, defined by the operator as regions of 
interest (ROI) (Figure 1a), were quantitatively analyzed with a dedicated software (Q-ontrast; e-
AMID—Advanced Medical Imaging Development, Italy distributed from Bracco). Q-ontrast 
generates chromatic maps (Figure 1b) of the ROI perfusion patterns, and automatically compensates 
for motion artifacts during data acquisition.
43
 The Q-ontrast analysis of ROI generated curves 
representing echo-signal intensity vs time (time intensity curves). For all patients time intensity 
curve parameters, including the slope of the first ascending tract of the curve, the curve shape, time 
to peak enhancement, the area under the curve, regional blood flow and mean transit time were 
recorded (Figures 1c–e).43 
 
 
 
Figure 1. (a) CEUS of an intestinal loop with aGVHD. The ROI is indicated by white arrow. (b) 
ROI quantitative analysis of BW vascularity with the Q-ontrast software with the corresponding 
color map (see text). (c) Representative TIC in Pt10 at I-aGVHD diagnosis. The curve has a 
‘tailing’ shape with a mean transit time (MTT)=46.3 s and AUC=5.1 cm2. (d) Representative TIC in 
the same patient (Pt10) after clinical response to steroids: MTT and AUC decreased (MTT=38.7 s, 
AUC=0.25 cm2). (e) Representative TIC in Pt10 at I-aGVHD flare: MTT and AUC increased again 
(MTT=92.6, AUC=2.6 cm2). A full color version of this figure is available at the Bone Marrow 
Transplantation journal online. 
Full figure and legend (133K) 
 
In all patients, US and CEUS were performed by a physician with 15 years of experience in US, 
who is a member and teacher of the Italian School of Basic and Emergency Ultrasound (SIUMB) at 
the University of Pisa. 
Statistical analysis 
Sensitivity, specificity, positive and negative predictive values were determined to evaluate the 
diagnostic accuracy of standard US and CEUS. Their point estimates and 95% CIs were reported. 
 
Results 
 
Standard US findings of I-GVHD (study group) 
Table 2 illustrates US and CEUS findings, and their correlation with GVHD and clinical outcomes. 
Standard US invariably revealed increased BWT mostly related to mucosal edema (Figure 2a). 
Segments involved varied from patient to patient. Of 14 patients, 9 had more than one site involved 
at the onset of symptoms. The BW layers could be identified in 11 patients, whereas in the others 
boundaries were poorly defined. 
 
 
 
Figure 2. Imaging of aGVHD by color-doppler US and EPs (1, 2, 3) by CEUS. (a) Macro-
vascularization of the terminal ileum with color-doppler US (arterioles). Increased BWT (5.3 mm), 
mostly due to mucosal edema. An echo-rich layer is detectable between the mucosal layer and the 
bowel lumen of the distal ileum (white arrow). (b) EP 1: arterial phase enhancement of 
microcirculation with complete enhancement of the entire wall section from mucosal to the serosal 
layer (green arrow). (c) EP 2: the contrast medium reaches and enhances the BW microcirculation 
during the arterial phase (green arrows), with absence of enhancement only in the outer border of 
the muscularis propria (red arrow). The ‘Vasa recta’ are identified by contrast medium (white 
arrowhead). (d) EP 3: arterial phase enhancement of microcirculation showing absence of 
enhancement (red arrow) both in the outer and in the inner border of the BW and enhancement of 
microcirculation only in the intermediate submucosal layer (green arrow). A full color version of 
this figure is available at the Bone Marrow Transplantation journal online. 
Full figure and legend (123K) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2 - Standard US and CEUS findings at diagnosis, at follow-up and at flare. 
 
 
 
 
 
 Standard US findings in the control group 
 
Healthy volunteers (N=6) and U-GVHD (N=16) patients had normal BWT thickness (Figure 3a).
8, 32
 
On the contrary, patients (N=4) with NEC showed BWT as for the study group (I-GVHD) (Figure 
3b).
27, 28
 
 
 
Figure 3. (a) Standard US of a normal volunteer showing normal BW thickness (BWT; 1.7 mm, 
white arrow). (b) Standard US in a patient with NEC showing BWT (28.2 mm, white arrow). (c) 
CEUS in a normal volunteer (control group) showing arterial phase enhancement of BW, and 
normal thickness. (d) CEUS in a patient with U-GVHD without I-GVHD (control group) showing 
arterial phase enhancement of BW, and normal thickness. White arrows show arterial enhancement. 
(e) CEUS with convex probe and (f) CEUS with high-frequency linear probe of the same patient 
with NEC showing BWT and arterial phase enhancement (white arrowhead). There is passage of 
microbubbles in the lumen (white arrows). 
 
CEUS findings in I-GVHD (study group) 
CEUS was performed at diagnosis, during treatments and follow-up (Table 2).
38
 CEUS was safely 
performed in all patients, including one with a baseline creatinine level of 4.5 mg/dL.40 Overall, by 
Q-ontrast software analysis, a rapid enhancement peak, due to a rich microvascularization of the 
BW, described by the tailing-curve shape and a long tailing, expressed by a prolonged mean transit 
time was observed in all patients (Figure 1c). 
Findings at diagnosis 
Overall, at aGVHD onset, during the arterial phase, CEUS showed three distinct enhancement 
patterns (EPs) of the bowel microcirculation: EP-1, a complete enhancement of the entire wall 
section from the mucosal to the serosal layer (Figure 2b); EP-2, enhancement of the entire wall with 
the exception of the outer border of the muscularis propria (Figure 2c); EP-3, enhancement of the 
intermediate submucosal layer without enhancement of the outer and inner borders of the BW 
(Figure 2d). Moreover, a persistent microcirculation enhancement longer than 2 min was seen 
during the venous washout in 11 of 14 patients. 
 
Follow-up findings 
All 14 patients with GVHD were promptly treated with steroids at 2 mg/kg. Salvage treatment in 
steroid-refractory patients consisted of Infliximab,
4, 44, 45
 Rituximab,
46, 47
 extracorporeal 
photophoresis,
48
 budesonide
49
 alone or in various combinations (Table 2). 
In patients who completely responded to treatment with normalization of standard US, CEUS 
showed similar findings as for healthy volunteers and U-GVHD patients (Figures 3c and d).
38
 
However, in patients with clinically relevant improvement but no complete response, CEUS showed 
persistent microvascular enhancement suggesting still active disease, while standard US showed 
normal findings. In steroid-refractory
50, 51
 patients, CEUS became normal only in those who 
achieved complete remission after salvage therapy, whereas it remained unchanged in patients who 
eventually died of GVHD-treatment-related complications (Table 2). In patients with improvement 
but no complete remission, US showed a sensitivity of 55% (95% CI: 0.23–0.83) and specificity of 
100% (95% CI: 0.19–1) with a positive predictive value of 100% (95% CI: 0.42–1) and negative 
predictive value of 38% (95% CI: 0.09–0.76), whereas CEUS showed a sensitivity of 100% (95% 
CI: 0.62–1) and specificity of 100% (95% CI: 0.62–1), with positive and negative predictive values 
of 100%. 
 
Findings at GVHD flare 
 
Overall, I-aGVHD flared in three patients (Table 2, Figure 1e). The CEUS BW EPs correlated with 
clinical symptoms. Standard US and CEUS showed normal features in responsive patients. In one 
patient who only showed a clinical improvement, CEUS showed persistent microvascular changes 
suggestive of subclinical activity. Qualitative assessment of BW microcirculation enhancement for 
each patient during follow-up and flare was in accordance with quantitative assessment using time 
intensity curves. Patients responding to treatment had a decrease in mean transit time and area under 
the curve (Figures 1c–e). 
 
CEUS findings in the control group 
 
CEUS showed a thin layer of enhancement of BW both in healthy volunteers (Figure 3c) and in U-
GVHD control patients (Figure 3d). These findings differed from those in the I-GVHD study group 
(Figures 2b–d). In patients with NEC, there was a strong arterial phase enhancement, suggestive of 
BW microvascular changes due to infection-related inflammation (Figures 3e and f).
27
 The US and 
CEUS findings in NEC patients were superimposable. 
We found penetration of microbubbles in the bowel lumen, not only in the study group as 
previously reported,
17, 18
 but also in one patient with NEC (Figures 3e and f). 
 
DISCUSSION 
 
Acute GVHD and its complications are major causes of non-relapse mortality following an 
allograft. Given the non-specific symptoms and the significant side effects of intestinal GVHD 
treatment, a histological diagnosis via endoscopic biopsies is highly recommended and may be 
required in up to 40% of patients for differential diagnosis.
52
 Reliable non-invasive procedures to 
evaluate its extension and treatment response are still lacking.
3, 4
 
We hypothesized that CEUS could specifically detect MVC at the onset of GVHD and during its 
treatment. Our hypothesis partly derives from the observations that intestinal biopsies during acute 
GVHD show an increased microvessel circulation
53
 and that graft-vs-host reactions are associated 
with increased neovascularization.
15
 In our study, standard US mostly revealed abnormal BWT in 
multiple segments suggestive of extensive intestinal involvement, as shown in a previously 
published study that employed positron emission tomography (PET).
54
 Increased BWT, due to 
mucosal edema, was consistently observed in both the small intestine and the colon as previously 
described by Klein et al.
5
 However, these non-specific findings are also found during several 
intestinal infections.
27, 28
 
CEUS clearly showed a microcirculation enhancement of the BWs during the arterial phase, 
followed by a prolonged venous phase washout. The persistence of the contrast agent in the BWs 
was expressed by the prolonged mean transit time. Interestingly, the EPs observed were similar to 
those described in active Crohn’s disease.25 The tailing shape of the washout curve may be 
explained by a marked inflammatory interstitial edema that may correlate with the pericapillary 
hemorrhage described in biopsies during active GVHD.
22
 The interstitial edema does not prevent 
the arterial in-flow but slows the circulation in the venules and is likely responsible for the 
prolonged venous phase washout.
23
 Furthermore, GVHD pathophysiology is characterized by 
neovascularization, mainly driven by vasculogenesis, during its early inflammatory phase. At a later 
stage, the vasculature itself becomes a target of allo-reactive donor T cells leading to fibrosis and 
rarefaction of blood vessels.
15
 Overall, the increased arterial microvascular enhancement may 
correlate with an early neovascularization of the BWs
15
 and the prolonged venous phase washout 
may be seen where the inflammatory interstitial edema is more prominent. 
GVHD response to treatments correlates with longer survival.
17
 In our study, complete clinical 
remission, after first-line or salvage treatment, coincided with normalization of both standard US 
and CEUS. However, patients with clinically relevant improvement without complete resolution of 
symptoms are a challenging subgroup at high risk of flare. Close follow-up is mandatory. Standard 
US only allows monitoring of BWT. On the contrary, CEUS allows us to detect microvascular 
changes at a capillary level, underlying persistent inflammatory activity, also in patients with 
normal BWT. Though the patient series was small (14 patients in the study group and 16 in the 
control group), CEUS was significantly more sensitive and specific than standard US in identifying 
subclinical GVHD activity, predictive of clinical flare, in patients without complete resolution of 
symptoms. Similarly, Di Sabatino et al.
24
 described a group of patients with clinically inactive 
Crohn’s disease who showed enhanced CEUS signal intensity. This group of patients developed 
early relapse. The authors suggested that CEUS findings were suggestive of subclinical disease 
activity that preceded early relapse.
24
 Moreover, Serra et al.
25
 reported a significant correlation 
between CEUS EPs and Crohn’s disease activity. These observations are similar to what we have 
seen in our I-GVHD patients with abnormal CEUS findings despite relevant improvement of 
symptoms. Moreover, US and CEUS allowed to rule out lower intestinal GVHD when patients only 
presented with U-GVHD. This could be particularly useful in U-GVHD patients who can be treated 
with lower doses of steroids, reducing their side effects, as compared with patients with midgut 
symptoms. 
CEUS is well tolerated, non-invasive and less expensive than other imaging techniques.
54
 
Moreover, it is applicable to patients with renal insufficiency, where CT or MRI with contrast 
media are contraindicated.
55
 The reported incidence of severe hypersensitivity or allergic events to 
CEUS contrast agents is extremely low (0.001%).
40
 
In conclusion, though not diagnostic, CEUS showed MVC of the BW that correlated with clinical 
symptoms of biopsy-proven I-GVHD and its treatment response at diagnosis, at follow-up and at 
flare. 
Importantly, even though US and CEUS findings were superimposable in patients at diagnosis and 
in complete clinical remission after treatment, CEUS was more sensitive and specific in identifying 
residual disease activity in high-risk patients with clinically relevant improvement but not complete 
resolution of symptoms. 
Moreover, CEUS provided a quantitative measurement of altered vasculature in segments 
inaccessible to endoscopic evaluation. Larger prospective studies are warranted to establish the role 
of the combination of clinical signs and/or symptoms with CEUS findings in the clinical follow-up 
of biopsy-proven I-GVHD. 
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